Researchers announced start of a new clinical trial in Winnipeg, Canada, and its surroundings that will focus on application of autologous mesenchymal stem cells for multiple sclerosis treatment.
Multiple sclerosis therapy that uses mesenchymal stem cells proves so far safe and not having adverse side effects, international Mesems project says.
UK scientists are about to launch a trial in which bone marrow stem cells will be used for multiple sclerosis treatment.
Stem cell technology has long offered the hope of regenerating tissue to repair broken or damaged neural tissue.All news
Cell Therapy Center EmCell offers multiple sclerosis (MS) treatment using fetal stem cells, with improvements reported in most cases. The goal of MS treatment is to terminate autoimmune aggression, that is, the internal attack against patient’s own nervous system, by disrupting the main mechanism of the disease. This, in turn, leads to the subsiding or even regression of neurological symptoms.
With MS, fetal stem cells have 2 major functions:
Over the last 21 years, Cell Therapy Center EmCell has treated some 200 patients with different forms of MS and achieved improvements in 85% of cases.
After stem cell treatment, our patients report a number of improvements:
Restoring the nervous system takes time and requires patience. A customized and integrated MS treatment at Cell Therapy Center EmCell lasts 5 days.
Subtypes of multiple sclerosis
Treatment of patients with remitting-relapsing multiple sclerosis
Treatment of patients with secondary progressive multiple sclerosis
Treatment of patients with primary progressive multiple sclerosis
Dynamics of neurological symptoms in 18 multiple sclerosis cases after the stem cell therapy
Patient H., 42. Multiple sclerosis
Patient V.A., 28. Multiple sclerosis
Patient H.R., 43. Multiple sclerosis; emphysema; pulmonary insufficiency
Patient L.N., 52. Multiple sclerosis
Patient R.W., 44. Primary progressive cerebrospinal multiple sclerosis with spastic paraparesis of the lower extremities
Patient D.M., 29. Remitting-relapsing multiple sclerosis
Patient M.C., 63. Secondary progressive multiple sclerosis with cerebrospinal involvement, spastic paraparesis of lower extremities and urine retention
Patient A.Z.D., 35. Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities and urine retention
Patient B. B., 36. Secondary progressive multiple sclerosis with cerebrospinal involvement and spastic paraparesis of the lower extremities. EDSS – 5,0. Urine incontinence. Moderate type 1 diabetes mellitus